Anesthesia Pharmacology
Chapter 7: Autonomic Cholinergic Pharmacology Practice Questions
Click on the correct answer.
Location(s) of cholinergic synaptic sites:
- neuromuscular junction
- autonomic effector sites innervated by post-ganglionic sympathetic fibers
- some CNS synapses
- A & C
- B & C
Factors that limit CNS effects of systemic acetylcholine: administration:
- poor CNS penetration
- inactivation by plasma butrylcholinesterase
- both
- neither
Localization of muscarinic cholinergic receptors:
- postganglionic parasympathetic effector sites
- autonomic ganglia cells
- adrenal medulla
- A & C
- A, B & C
Cholinergic receptor type primarily localized at skeletal muscle neuromuscular junctions:
- muscarinic
- nicotinic
Highly sensitive to the action of acetylcholinesterase:
- carbachol
- bethanechol (Urecholine)
- acetylcholine
- A & C
- A,B, & C
Muscarinic receptor subtype primarily associated with the heart:
- M1
- M2
- M3
- M4
Effective antagonist at neuromuscular junction receptors;
- atropine
- tubocurarine
Most likely to be effective in blocking all ganglionic neurotransmission:
- tubocurarine
- mecamylamine (Inversine)
- atropine
- all of the above
Cardiac muscarinic Type M2-receptor mediated action(s):
- increased phase 4 depolarization rate
- increased AV nodal conduction velocity
- Decreased atrial and ventricular contractility
- all the above
Ligand-gated ion channels:
- nicotinic
- muscarinic
- both
- neither
Tends to cause fast responses:
- nicotinic
- muscarinic
Agonist effects blocked by tubocurarine:
- muscarinic receptors
- nicotinic receptors
Indirect-acting cholinomimetic:
- atropine
- edrophonium (Tensilon)
- carbachol
- acetylcholine
- ephedrine